Ipamorelin modified with meta-carborane creates a potent, boron-rich ghrelin receptor agonist for cancer therapy
Background
Boron Neutron Capture Therapy (BNCT) is a promising binary cancer therapy that combines a boron-containing drug with localized radiation. The therapy's success hinges on selectively delivering a high concentration of boron atoms to tumor cells while sparing healthy tissue. A significant challenge in BNCT has been achieving this targeted delivery. One strategy involves exploiting G protein-coupled receptors, like the ghrelin receptor (GHSR), which are often overexpressed on various cancer cells. Using peptidic ligands that bind to these receptors can serve as a shuttle system, directing boron specifically to the tumor. This study explores creating novel peptide-boron conjugates to improve the efficacy and specificity of BNCT.
Study Design
Researchers designed and synthesized a novel hexapeptide super-agonist and modified it with various carborane monoclusters. They evaluated these conjugates for their ability to activate the ghrelin receptor (GHSR). The most promising building block, a meta-carborane with a mercaptoacetic acid linker, was selected based on its chemical stability and the resulting conjugate's activation efficacy. The team then applied this modification strategy to the backbones of known ghrelin receptor ligands, Ipamorelin and Growth Hormone Releasing Peptide 6 (GHRP-6), to generate new, highly potent, boron-loaded peptide conjugates.
Results
The study successfully identified an optimal method for creating boron-rich peptide agonists targeting the ghrelin receptor. A specific meta-carborane building block with a mercaptoacetic acid linker was found to be ideal for peptide modification. This was due to its superior chemical stability and its ability to produce a conjugate with suitable ghrelin receptor activation efficacy. The versatility of this approach was confirmed by its successful application to existing peptides.
The research demonstrated the generation of highly potent, boron-loaded conjugates using the backbones of the known
ghrelin receptorligands, Growth Hormone Releasing Peptide 6 and Ipamorelin. This establishes a viable strategy for developing peptidic boron delivery agents for cancer therapy by leveraging receptors overexpressed on tumor cells.
Key Findings
- A meta-carborane building block with a mercaptoacetic acid linker was optimal for creating stable, active peptide-boron conjugates.
- Researchers designed a novel hexapeptide super-agonist targeting the ghrelin receptor.
- The versatile carborane modification was successfully applied to the known peptides GHRP-6 and Ipamorelin.
- The resulting boron-loaded conjugates of Ipamorelin and GHRP-6 were described as 'highly potent' activators of the ghrelin receptor.
Why It Matters
This research provides a proof-of-concept for a sophisticated drug delivery system in oncology, specifically for Boron Neutron Capture Therapy. By successfully attaching a stable boron cluster to peptides like Ipamorelin without losing their high potency at the ghrelin receptor, it opens a new avenue for selectively targeting cancer cells that overexpress this receptor. For future clinical applications, this could lead to more effective and less toxic cancer treatments. The key takeaway is the validation of a stable meta-carborane linker as a tool for creating boron-rich peptide therapeutics. This work is preclinical, and significant further research is needed to evaluate the in vivo boron delivery, tumor accumulation, and therapeutic efficacy before it can be translated into a usable human protocol.
